




The relative strengths and weaknesses of PUMA Biotechnology INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PUMA Biotechnology INC compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 19% points. The greatest weakness of PUMA Biotechnology INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 63% points.

The company's Economic Capital Ratio, given in the ranking table, is 124%, being 128% points below the market average of 252%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	106,394	Assets	165,525
Cost of Goods Sold	0	Liabilities	112,223
Intangible Assets	0	Expenses	320,075
Liabilities, Current	58,340	Revenues	27,685
Liabilities, Non-Current	0	Stockholders Equity	53,302
Other Assets	54,661	Net Income	-291,955
Other Compr. Net Income	13	Comprehensive Net Income	-291,948
Other Expenses	5,572	BaseVar	312,978
Other Liabilities	53,883	ECR before LimitedLiability	-127%
Other Net Income	435	Economic Capital Ratio	124%
Other Revenues	27,685		
Property and Equipment	4,470		
Research and Development	207,810		
Selling, General and Administrative Expense	106,693		